Compare Johnson & Johnson (JNJ) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Schwab US Dividend Equity ETF — how do they compare? Johnson & Johnson trades at $249.56 (market cap $598.96B), while Schwab US Dividend Equity ETF trades at $32.78. The key difference: Johnson & Johnson pays a 2.15% dividend while Schwab US Dividend Equity ETF pays none, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Johnson & Johnson nearer its low. Which is the better fit depends on your goals.
| JNJ | SCHD | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Broad Market / Factor |
52-Week High | $267.24 | $33.04 |
52-Week Low | $164.36 | $26.38 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
SCHD trades at $32.75, down 0.49% on the day, with strong technical momentum showing 17 bullish signals versus no sell signals. The ETF has delivered approximately 20% returns year-to-date in 2026, outperforming both the S&P 500 and Nasdaq-100. Recent news highlights SCHD's defensive sector allocation and dividend sustainability as key strengths amid market volatility.
The outlook remains positive given SCHD's focus on quality dividend stocks with 10+ years of payment history. Key opportunities include defensive positioning against AI bubble risks and consistent income generation. Risks include potential underperformance during growth stock rallies and sector concentration in healthcare and consumer defensive sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
